Last updated 2026-07-26
- Raised $2.7M Seed round led by FutuRx, Aug 2018
Total raised
$2.7M
Last: Undisclosed Round 2018-09
Stage
Seed
Founded
2018
Headcount
3
HQ
Ness Ziona, Israel
Sector
Health Tech & Life Sciences
About
Bsense Bio Therapeutics is developing dual cationic channel small molecule modulators for the treatment of sensory hyperexcitability-related disorders. The company is pioneering a novel approach targeting multiple hyperexcitability-related mechanisms using a single compound, which aims to achieve greater efficacy and safety. Their approach is based on targeting two cation channels, TRPV1 and Kv7.2/3, which are co-localized on sensory nociceptive neurons and are recognized as key players in modulating neuronal excitability. The company has generated preclinical proof-of-concept in chronic pain and is also generating data in additional hyperexcitability indications such as Pruritus and Tinnitus.
Funding history · 1 round · $2.7M total
2018-08
Seed
$2.7M
★ FutuRx★ OrbiMed★ Takeda Ventures★ Israel Innovation Authority★ Johnson & Johnson Innovation
Headcount over time
From 6 (2020-10) to 4 (2023-10) · -2 (-33%) · 6 points · source: Finder history + radar grounding
Q&A
- What is Bsense Bio Therapeutics' primary focus?
- Bsense Bio Therapeutics is developing small molecules biotechnology designed to treat sensory hyperexcitability-related disorders.
- When was Bsense Bio Therapeutics founded?
- Bsense Bio Therapeutics was founded in September 2018.
- How many employees does Bsense Bio Therapeutics currently have?
- Bsense Bio Therapeutics has 1-10 employees.
- What is Bsense Bio Therapeutics' total funding to date?
- Bsense Bio Therapeutics has raised a total of $2,700,000 USD.
- When did Bsense Bio Therapeutics raise its Seed round?
- Bsense Bio Therapeutics raised a Seed round in September 2018, securing $2,700,000 USD.
- What is the company's approach to treating sensory hyperexcitability-related disorders?
- Bsense Bio Therapeutics is pioneering a novel approach targeting multiple hyperexcitability-related mechanisms using a single compound, specifically targeting two cation channels, TRPV1 and Kv7.2/3.
- What is the current product stage of Bsense Bio Therapeutics?
- Bsense Bio Therapeutics is currently in the R&D product stage.
- What is the primary sector of Bsense Bio Therapeutics?
- The primary sector of Bsense Bio Therapeutics is Health Tech & Life Sciences.
Team · 2
Prof. Bernard Attali
Founder · Inventor of the technology
Dr. Asher Peretz
Founder · Co-founder
Sectors & technology
Primary sector
Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & Development
Technologies
BiologicalsMolecules
Target customers
Healthcare & Life SciencesLife SciencesBiotechnologyPharmaceuticals
Business model
B2B
Highlights
Verified
Tags
pharmaceuticalsneurologybiotechnologydiabetestargeted-therapytreatmentspharma-companies
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
External links
| Website | futurx.co.il/cgi-sys/suspendedpage.cgi |
|---|
Identifiers & details
| Legal name | BSENSE BIO THERAPEUTICS LTD |
|---|---|
| Founded | 2018-9 |
| Employees (exact) | 3 |
Radar intelligence
Patents
| EPO | 2 |
|---|
Web history (Wayback)
| Domain | futurx.co.il |
|---|
Certificate / subdomain footprint
| Subdomains | 10 |
|---|
Israeli Companies Registrar (רשם החברות / ICA)
| Registrar # (ח.פ.) | 515817088 |
|---|---|
| Status | פעילה |
| Corp type | ישראלית חברה פרטית |
| Incorporated | 2018-03-18 |
| Purpose | לעסוק בכל עיסוק חוקי |
| Liability | מוגבלת |
| In violation (unfiled) | no |
| Last annual report | 2025 |
| Active charges / liens | 0 |
| Registry events | 8 — shares_capital (5), people (3) |
| Registered address | רמון אילן 2 נס ציונה |
Recent registry events
| Date | Event |
|---|---|
| 2025-10-28 | הקצאת מניות |
| 2025-07-27 | עדכון בעלי תפקידים |
| 2026-02-24 | עדכון דירקטורים-הוספת דירקטור |
| 2026-02-24 | עדכון דירקטורים-הסרת דירקטור |
| 2025-10-20 | שינוי בהרכב הון - מניות-שינוי סוג מניה |
| 2025-10-20 | שינוי בהרכב הון - מניות-שינוי ערך נקוב |
| 2025-10-20 | העברת מניות |
| 2025-08-07 | הגדלה של הון רשום |